N/A N=60 Effectiveness of Using an Oil Bath Additive
Xerosis Cutis
Primary: Transepidermal Water Loss (TEWL) in g/m2/h at the Left Mid Volar Forearm — 10.0; 11.9 g/m2/h — p=0.002
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=200 A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier
Dermatitis, Atopic
Primary: Skin Barrier Strengthening Effect by Measurement of Trans Epidermal Water Loss (TEWL) Before and After Induction of Skin Irritation — 19.790; 24.680; 29.648; 28.646 TEWL…
N/A N=133 Skin Health and Effectiveness of Standardized Skin Care Regimens in Nursing Home Residents
Xerosis Cutis
Primary: Change From Baseline in Overall Dry Skin Score (ODS) — -0.9; -1.2; -0.9 units on a scale
N/A N=66 A Proof of Concept Clinical Study to Investigate the Effects of an Experimental Cosmetic Moisturiser on the Barrier Function of Human Skin on the Face and Forearm
Skin Care
Primary: Change From Baseline in Transepidermal Water Loss (TEWL) Measurements on Day 29, Test Product Treated Versus (vs.) Untreated Sites on the Forearm — -0.59; 0.79 gram…
N/A N=54 The Role of Skin Care Regimen in Skin Health
Itching · Xerosis
Primary: Change in Total Clinical Score (TCS) Between the Final Visit and Baseline — -4; -2 score on a scale
N/A N=149 To Evaluate the Effect of Moisturizing Creams on Skin Barrier Function
Dry Skin · Skin Care
Primary: Change From Baseline in Trans-epidermal Water Loss (TEWL) Following Application of Test Regimen on Face (Area 1 Compared to Area 2) at Day 29 — -5.077; -4.946; -3.692…
Phase 3 N=51 A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin
Eczema
Primary: Eczema Area and Severity Index (EASI) on Day 3 - Change From Baseline — -1.783; -0.767 units on a scale — p=<0.0001
Phase 2 N=53 Trial to Determine the Therapeutic Benefit of an OTC Cream on Dry, Itchy Skin of Adults and Children With Eczema
Atopic Dermatitis
Primary: Change From Baseline in the Itch Assessment Score Immediately Following Treatment — 1.93; 2.64 units on a scale — p=<0.001
N/A N=121 A Clinical Investigation With Epaderm® Cream
Eczema · Psoriasis · Dry Skin; Eczema
Primary: Number of Participants With Improved Skin Moisturization — 114 Participants
N/A N=120 Cetaphil Restoraderm Effect on Young Children With Atopic Dermatitis
Atopic Dermatitis
Primary: Time to Relapse (Quantile 25%) — 48; 15 Days
N/A N=1,260 A Community-based Assessment of Skin Care, Allergies, and Eczema
Atopic Dermatitis · Atopic Disorders · Eczema
Primary: Provider-diagnosed Atopic Dermatitis — 217.7; 268.5 Participants with imputed values — p=0.019
N/A N=42 Compatibility of a Mild, Moisturizing Hand Cleanser for Patients With Mild to Moderate Hand Dermatitis
Hand Dermatosis
Primary: Investigator Global Assessment — 1.0; 1.1 units on a scale
N/A N=100 Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants
Atopic Dermatitis
Primary: Percentage of Participants With Cumulative Atopic Dermatitis Diagnosed by Investigator at 12 Months — 13.2; 25 Percentage of participants
N/A N=41 Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema
Atopic Dermatitis (AD)
Primary: Percentage With Erythema on the Face at Baseline Before Investigational Product Application — 33.3; 71.9; 55.6; 6.3 Percentage of participants
Phase 4 N=528 CeraVe Diabetes Mellitus
Diabetes Complications
Primary: Percentage of Participants Reporting Adverse Events (AE) — 0 percentage of participants
N/A N=31 A Tolerability Assessment Study of Three Wash Products in Infants
Skin Care
Primary: Tolerability Assessment of Test Products — 9; 10; 11; 1 Participants
N/A N=132 A Study to Evaluate of Cosmetic Benefit of a Moisturising Cream in People With Blemish Prone Skin
Skin Care
Primary: Change From Baseline in Corneometer Values at 8 Hours on Day 1 — 6.14; 2.63; 3.60 Arbitrary Corneometer unit — p=0.0128
Phase 4 N=30 Adjunctive Usage of a Moisturizing Lotion (Cetaphil® Moisturizing Lotion) to Limit the Skin Irritation Linked to the Set-Up of a Treatment by Topical Retinoid (Differin® Gel 0,1%) in Healthy Subjects of Chinese Origins
Healthy Skin
Primary: Erythema Rating Scale — 0.6; 0.7 units on a scale
N/A N=24 Human Comedogenicity Test
Comedogenicity
Primary: Microcomedone Score of Follicular Biopsies — 0.84; 0.97 microcomedone score — p=0.274
Phase 3 N=236 Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis
Uremic Xerosis
Primary: Treatment Response of Xerosis — 71; 48 participants
Phase 2 N=22 An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis
Atopic Dermatitis
Primary: Incidence of Skin Irritation — 0 Participants
Phase 4 N=20 A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change of Trans Epidermal Water Loss (TEWL) With Use of Eucerin Lotion — 21.4 percent change
N/A N=72 Proof of Concept Anti-ageing Clinical Study in Healthy Subjects
Skin Aging
Primary: Change From Baseline in Ra (a dermaTOP Parameter), of Test Product Treated Versus (vs.) Untreated Side at Day 29 — -1.90; -0.12 Micro meter (µm) — p=0.0638
Phase 4 N=128 Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test
Skin Irritation
Primary: Area of Erythema and Elevated Responses of Skin to Product — 91; 68; 33; 42 participants
Phase 4 N=50 A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients
Acne Vulgaris
Primary: The Primary Endpoint is the Change in Corneometry Reading Between the Two Sides of the Face Treated With Winlevi Versus no Treatment. — 131.27; 113.94 microSiemens (μS)…
N/A N=17 Effect of a Basic Skin Care Product on the Structural Strength of the Skin
Healthy Skin
Primary: Blistering Time (Full Blister) — 63; 54; 65; 62 Minutes
N/A N=99 Skin Care for Cancer Patients: A Product Satisfaction Survey
Skin Toxicity
Primary: Product Satisfaction of the Following Test Articles A, B, and C: Lindi Skin Soothing Balm (Product A), Lindi Skin Face Serum (Product B), and Lindi Skin Face Wash…
Phase 3 N=120 An Efficiency of a Moisturizer Containing Licochalcone A, L-carnitine and 1,2-decanediol With Adapalene Gel in Acne
Acne
Primary: Reduction of Undesirable Effects — 26; 38; 35; 10 participants — p=0.001
N/A N=167 Prevention of Incontinence-associated Dermatitis
Incontinence-associated Dermatitis
Primary: Incidence of Incontinence-associated Dermatitis (IAD) — 18; 8; 5; 5 Participants
N/A N=12 Comparing the Effects of Three Different Dressings on the Cutaneous Response of Sacral Skin
Pressure Ulcer Prevention
Primary: Change in Skin Surface Temperature From Baseline — 3.1; 3.8; 3.0; 3.3 °C